Advanced Renal Cell Carcinoma
Also known as:Advanced Renal Cell Cancer/Advanced Renal Cell Carcinoma (aRCC)/Advanced Renal Cell Carcinoma (RCC)/Adenocarcinoma of kidney/Renal cell cancer/Renal cell carcinoma stage unspecified/Grawitz tumor/Renal cell carcinoma NOS/Renal cell adenocarcinoma/Grawitz tumour/Renal cell carcinoma (disorder)/Renal cell carcinoma/Renal cell carcinoma (morphologic abnormality)/Carcinoma, Renal Cell/Clear cell carcinoma of kidney (disorder)
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB11945 | Avelumab | A monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma. |
| DB06626 | Axitinib | An oral VEGFR and kinase inhibitor used for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. |
| DB08875 | Cabozantinib | A tyrosine kinase inhibitor used to treat advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. |
| DB09078 | Lenvatinib | A receptor tyrosine kinase inhibitor used for the treatment of metastatic thyroid cancer, advanced renal cell carcinoma in combination with everolimus, and unresectable hepatocellular carcinoma. |
| DB09035 | Nivolumab | A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma. |
| DB06589 | Pazopanib | An antineoplastic agent used in the treatment of advanced renal cell cancer and advanced soft tissue sarcoma in patients with prior chemotherapy. |
| DB09037 | Pembrolizumab | A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma. |
| DB00398 | Sorafenib | A kinase inhibitor used to treat unresectable liver carcinoma, advanced renal carcinoma, and differentiated thyroid carcinoma. |
| DB06287 | Temsirolimus | A antineoplastic agent used in the treatment of renal cell carcinoma (RCC) that works by inhibiting mTOR. |
| DB11800 | Tivozanib | A kinase inhibitor to treat adult patients with renal cell carcinoma (RCC) who have failed prior systemic therapies or experienced relapsed disease. |
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB00062 | Albumin human | 1 | Recruiting | 1 |
| DB11595 | Atezolizumab | 1 | Recruiting | 1 |
| DB06626 | Axitinib | 1 | Recruiting | 1 |
| DB08875 | Cabozantinib | 1 | Recruiting | 3 |
| DB06091 | Evofosfamide | 1 | Unknown Status | 1 |
| DB06186 | Ipilimumab | 1 | Active Not Recruiting | 1 |
| DB09078 | Lenvatinib | 1 | Recruiting | 1 |
| DB09035 | Nivolumab | 1 | Active Not Recruiting | 1 |
| DB09035 | Nivolumab | 1 | Recruiting | 2 |
| DB01229 | Paclitaxel | 1 | Recruiting | 1 |
| DB11595 | Atezolizumab | 1 / 2 | Recruiting | 1 |
| DB11945 | Avelumab | 1 / 2 | Recruiting | 1 |
| DB00531 | Cyclophosphamide | 1 / 2 | Recruiting | 1 |
| DB11714 | Durvalumab | 1 / 2 | Recruiting | 1 |
| DB01073 | Fludarabine | 1 / 2 | Recruiting | 1 |
| DB17475 | 不完全弗氏佐剂 | 1 / 2 | Unknown Status | 1 |
| DB05258 | Interferon alfa | 1 / 2 | Completed | 1 |
| DB09078 | Lenvatinib | 1 / 2 | Not Yet Recruiting | 1 |
| DB15721 | Natural Killer Cell | 1 / 2 | Recruiting | 1 |
| DB09035 | Nivolumab | 1 / 2 | Recruiting | 1 |
| DB06589 | Pazopanib | 1 / 2 | Completed | 1 |
| DB09037 | Pembrolizumab | 1 / 2 | Recruiting | 1 |
| DB05992 | Plinabulin | 1 / 2 | Recruiting | 1 |
| DB11595 | Atezolizumab | 2 | Recruiting | 1 |
| DB06626 | Axitinib | 2 | Terminated | 1 |
| DB00112 | Bevacizumab | 2 | Completed | 1 |
| DB08875 | Cabozantinib | 2 | Completed | 2 |
| DB08875 | Cabozantinib | 2 | Recruiting | 1 |
| DB14988 | Dalantercept | 2 | Terminated | 1 |
| DB01070 | Dihydrotachysterol | 2 | Completed | 1 |
| DB00530 | Erlotinib | 2 | Recruiting | 1 |
| DB01590 | Everolimus | 2 | Recruiting | 1 |
| DB09398 | Fluoride ion F-18 | 2 | Recruiting | 1 |
| DB05304 | Girentuximab | 2 | Recruiting | 1 |
| DB06186 | Ipilimumab | 2 | Active Not Recruiting | 1 |
| DB06186 | Ipilimumab | 2 | Recruiting | 1 |
| DB09078 | Lenvatinib | 2 | Recruiting | 1 |
| DB06080 | Linifanib | 2 | Completed | 1 |
| DB13982 | Lutetium Lu-177 | 2 | Recruiting | 1 |
| DB09035 | Nivolumab | 2 | Active Not Recruiting | 1 |
| DB09035 | Nivolumab | 2 | Recruiting | 2 |
| DB01269 | Panitumumab | 2 | Completed | 2 |
| DB06589 | Pazopanib | 2 | Completed | 1 |
| DB11972 | Rilotumumab | 2 | Completed | 1 |
| DB00398 | Sorafenib | 2 | Completed | 2 |
| DB01268 | Sunitinib | 2 | Completed | 2 |
| DB15232 | Telaglenastat | 2 | Completed | 1 |
| DB06287 | Temsirolimus | 2 | Completed | 1 |
| DB12056 | Trebananib | 2 | Completed | 3 |
| DB06626 | Axitinib | 2 / 3 | Not Yet Recruiting | 1 |
| DB01590 | Everolimus | 2 / 3 | Not Yet Recruiting | 1 |
| DB11679 | Fruquintinib | 2 / 3 | Not Yet Recruiting | 1 |
| DB15765 | Sintilimab | 2 / 3 | Not Yet Recruiting | 1 |
| DB06186 | Ipilimumab | 3 | Active Not Recruiting | 1 |
| DB09035 | Nivolumab | 3 | Active Not Recruiting | 1 |
| DB00398 | Sorafenib | 3 | Completed | 2 |
| DB01268 | Sunitinib | 3 | Active Not Recruiting | 1 |
| DB01268 | Sunitinib | 3 | Terminated | 1 |
| DB11800 | Tivozanib | 3 | Completed | 2 |
| DB11945 | Avelumab | Not Available | Recruiting | 1 |
| DB06626 | Axitinib | Not Available | Completed | 1 |
| DB06626 | Axitinib | Not Available | Recruiting | 1 |
| DB00398 | Sorafenib | Not Available | Completed | 2 |
| DB01268 | Sunitinib | Not Available | Completed | 1 |
| DB06287 | Temsirolimus | Not Available | Completed | 1 |